SinoPharm: COVID-19 vaccine could be ready by end of 2020 – Global Times
|In an interview with China’s highly influential media outlet, Global Times, Liu Jingzhen, Chairman of China National Pharmaceutical Group (SinoPharm), said the results of phase I and II clinical trials of the coronavirus vaccine were very positive and without serious side effects.
Key quotes
"SinoPharm was approved at the end of June to begin international phase III clinical trials and [the vaccine] could be on the market by the end of the year."
“Phase III trials should be completed in about three months and are in the final stages of approval.”
"So far, it's going well. It is leading the world in research and development, clinical trials, manufacturing facilities, and vaccine efficacy, safety, and accessibility."
In the US, three vaccines were under research and development in the first half, including those from Moderna and Pfizer.
Other COVID-19 vaccines are also in development - including one at the University of Oxford in the UK - and have also entered clinical trials.
Market reaction
The risk sentiment remains tepid amid intensifying US-China tensions over the Houston consulate episode. This negates any optimism over the vaccine hopes and economic recovery so far this Thursday.
AUD/USD trades listless around 0.7135 while S&P 500 futures also lack a clear direction to trade above 3,250. Meanwhile, the Asian equities trade mostly lower, with Japanese markets closed on a long break.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.